These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15620562)

  • 21. Pediatric vaccines. Gates launches $100 million initiative.
    Ferber D
    Science; 1998 Dec; 282(5396):1971. PubMed ID: 9874642
    [No Abstract]   [Full Text] [Related]  

  • 22. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
    Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
    Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Affordably priced new drugs for poor populations: Approaches for a global solution.
    Mossialos E; Dukes G
    Int J Risk Saf Med; 2001; 14(1):1-29. PubMed ID: 22388482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seizing market shaping opportunities for vaccine cold chain equipment.
    Azimi T; Franzel L; Probst N
    Vaccine; 2017 Apr; 35(17):2260-2264. PubMed ID: 28364940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introducing multiple vaccines in low- and lower-middle-income countries: issues, opportunities and challenges.
    Gordon WS; Jones A; Wecker J
    Health Policy Plan; 2012 May; 27 Suppl 2():ii17-26. PubMed ID: 22513729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shifts in global immunisation goals (1984-2004): unfinished agendas and mixed results.
    Hardon A; Blume S
    Soc Sci Med; 2005 Jan; 60(2):345-56. PubMed ID: 15522490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UNICEF asks donors to give poorer nations longer-term commitment.
    Ahmad K
    Lancet; 2002 Jun; 359(9322):2009. PubMed ID: 12076567
    [No Abstract]   [Full Text] [Related]  

  • 28. Approved but non-funded vaccines: accessing individual protection.
    Scheifele DW; Ward BJ; Halperin SA; McNeil SA; Crowcroft NS; Bjornson G
    Vaccine; 2014 Feb; 32(7):766-70. PubMed ID: 24374500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
    Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
    Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term solutions for the problem of vaccine shortages.
    Lattanzi M; Rappuoli R
    Expert Opin Biol Ther; 2004 Jun; 4(6):989-92. PubMed ID: 15174980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic analyses of rubella and rubella vaccines: a global review.
    Hinman AR; Irons B; Lewis M; Kandola K
    Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing supply side barriers to introduction of new vaccines to the developing world.
    McElligott S
    Am J Law Med; 2009; 35(2-3):415-41. PubMed ID: 19697757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Government financing for health and specific national budget lines: the case of vaccines and immunization.
    Lydon P; Beyai PL; Chaudhri I; Cakmak N; Satoulou A; Dumolard L
    Vaccine; 2008 Dec; 26(51):6727-34. PubMed ID: 18625279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine Prices: A Systematic Review of Literature.
    Hussain R; Bukhari NI; Ur Rehman A; Hassali MA; Babar ZU
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33137948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic aspects of vaccines and immunizations.
    Hinman AR
    C R Acad Sci III; 1999 Nov; 322(11):989-94. PubMed ID: 10646095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
    Mahoney RT; Krattiger A; Clemens JD; Curtiss R
    Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug makers to cut prices for developing countries.
    AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.